Skip to main content
Clinical Trials/ISRCTN87407792
ISRCTN87407792
Completed
未知

SeconDary Stroke PreVEntion ThRough Pathway ManagemenT (DiVERT Stroke)

Medtronic (United States)0 sites6,536 target enrollmentMarch 15, 2021

Overview

Phase
未知
Intervention
Not specified
Conditions
Stroke
Sponsor
Medtronic (United States)
Enrollment
6536
Status
Completed
Last Updated
last year

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
March 15, 2021
End Date
March 19, 2024
Last Updated
last year
Study Type
Observational
Sex
All

Investigators

Sponsor
Medtronic (United States)

Eligibility Criteria

Inclusion Criteria

  • Current inclusion criteria as of 01/09/2022:
  • US Inclusion Criteria:
  • 1\. Patients with a cryptogenic stroke or large artery atherosclerosis or small vessel occlusion hospitalization between 2017 – 2019
  • 2\. Age \=18 years
  • UK Inclusion Criteria:
  • 1\. Patients with a cryptogenic stroke or large artery atherosclerosis or small vessel occlusion hospitalization between 2019\-2020\. If ischemic stroke sub\-type classification proves to be difficult (i.e., small sample size), patients with an ischemic stroke from 2017\-2019 will be included.
  • 2\. Age \=18 years
  • Previous inclusion criteria from 20/05/2021 to 01/09/2022:
  • 1\. Patients with a cryptogenic stroke or large artery atherosclerosis or small vessel occlusion
  • hospitalization between 2017 – 2019

Exclusion Criteria

  • Current exclusion criteria as of 20/05/2021:
  • Does not meet inclusion criteria
  • Previous exclusion criteria:
  • 1\. Any history of the following through index stroke:
  • 1\.1\. Lacunar stroke
  • 1\.2\. Large artery atherosclerosis
  • 1\.3\. Diagnosis of AF or atrial flutter
  • 1\.4\. Ablation for AF or atrial flutter
  • 1\.5\. OAC use
  • 1\.6\. Methamphetamines drug use

Outcomes

Primary Outcomes

Not specified

Similar Trials